[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588299":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":27,"locations":33,"responsibleParty":50,"collaborators":11,"id":52,"slug":11,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":11,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":11,"enrollmentInfo":60,"targetDuration":11,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":11,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Celltrion","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CT-P51","EXPERIMENTAL",null,[13],"Drug: CT-P51",{"label":15,"type":16,"description":11,"interventionNames":17},"EU-approved Keytruda","ACTIVE_COMPARATOR",[18],"Drug: EU-approved Keytruda",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","CT-P51 200mg with pemetrexed and cisplatin or carboplatin will be administered every 3 weeks for a maximum of 4 cycles followed by CT-P51 or Keytruda and pemetrexed every 3 weeks",[9],{"type":21,"name":15,"description":25,"armGroupLabels":26,"otherNames":11},"Keytruda 200mg with pemetrexed and cisplatin or carboplatin will be administered every 3 weeks for a maximum of 4 cycles followed by CT-P51 or Keytruda and pemetrexed every 3 weeks",[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Jaeyoung Jang","CONTACT","+82 32 850 5769","jaeyoung.jang@celltrion.com",[34],{"facility":35,"status":36,"city":37,"state":11,"zip":11,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"ltd \"Institute of Clinical Oncology\"","RECRUITING","Tbilisi","Georgia",{"type":40,"coordinates":41},"Point",[42,43],44.83412,41.69143,{"lat":43,"lon":42},[46],{"name":47,"role":30,"phone":48,"phoneExt":11,"email":49},"Vladimer Kuchava","+995 995322 93306163","ladokuchava@gmail.com",{"type":51,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100588299",false,"NCT06939595","A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer","A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P51 and Keytruda in Combination With Platinum-Pemetrexed Chemotherapy in Patients With Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Stage IV, non squamous NSCLC\n* Have not received any prior systemic anti-cancer therapy for metastatic NSCLC\n* Have at least 1 measurable lesion per RECIST version 1.1\n\nExclusion Criteria:\n\n* Have predominantly squamous cell histology NSCLC.\n* Hypersensitivity or contraindication to any component of the study drug, pemetrexed and cisplatin or carboplatin","ALL","18 Years",{"count":61,"type":62},606,"ESTIMATED","INTERVENTIONAL",[65],"PHASE3","The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P51 and European Union (EU) approved Keytruda in combination with platinum pemetrexed chemotherapy in patients with previously untreated metastatic nsNSCLC.",[68],"Non Squamous Non Small Cell Lung Cancer","2025-04-21",{"date":71,"type":72},"2025-04-23","ACTUAL",{"date":74,"type":72},"2025-01-30",{"date":76,"type":62},"2028-07",{"name":5,"class":6},1]